Clinical Trials for Sarcoma

Phase 1 Trial With GD2-SADA:177Lu-DOTA Drug Complex in Patients With Recurrent or Refractory Metastatic Solid Tumors Known to Express GD2, Including Small Cell Lung Cancer, High Risk Neuroblastoma, Sarcoma and Malignant Melanoma

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Patients with recurrent or refractory metastatic GD2-expressing solid tumors, including small-cell lung cancer, high-risk neuroblastoma, sarcoma, and melanoma, receive GD2-SADA followed by ¹⁷⁷Lu-DOTA. GD2-SADA binds tumor-associated GD2 and captures the radioactive payload to concentrate radiation in tumors.

ClinicalTrials.gov ID: NCT05130255

A Phase I Study of Autologous Activated T-Cells Expressing a 2nd Generation GD2 Chimeric Antigen Receptor, IL-15, and iCaspase9 Safety Switch Administered To Patients With Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults and children with relapsed or refractory high-risk neuroblastoma or osteosarcoma receive cyclophosphamide/fludarabine lymphodepletion followed by autologous GD2-targeted CAR T cells. The cells express IL-15 to enhance expansion and persistence and include an inducible caspase-9 safety switch.

ClinicalTrials.gov ID: NCT03721068

A Phase 1 Open-Label, Dose-Escalation and Dose-Expansion Study to Investigate the Safety, Pharmacokinetics, and Anti-Tumor Activity of IACS-6274 as Monotherapy and in Combination in Patients With Advanced Solid Tumors

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously treated advanced solid tumors and ECOG performance status 0–1 receive IACS-6274, an investigational glutaminase-1 inhibitor, alone or with bevacizumab plus weekly paclitaxel or with the AKT inhibitor capivasertib. Combination cohorts focus on platinum-resistant ovarian cancer, KEAP1/NFE2L2-mutant non-small cell lung cancer, or low-ASNS high-grade serous ovarian cancer.

ClinicalTrials.gov ID: NCT05039801

Pilot Pharmacokinetic Study of VAL-413 (Orotecan®) in Patients With Recurrent Pediatric Solid Tumors

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Children and young adults aged 1–30 years with recurrent solid or CNS tumors and no curative treatment option receive oral VAL-413, a flavored irinotecan formulation whose active metabolite inhibits topoisomerase I, plus oral temozolomide. The study evaluates dosing and pharmacokinetics, including a first-cycle comparison with the intravenous irinotecan formulation taken orally.

ClinicalTrials.gov ID: NCT04337177

A Multi-Institution Study of TGFβ Imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherapy in Combination With Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Pediatric Bone and Soft Tissue

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Patients aged 2–40 years with measurable relapsed or refractory osteosarcoma, Ewing sarcoma, rhabdomyosarcoma, or eligible non-rhabdomyosarcoma soft-tissue sarcoma receive gemcitabine and docetaxel plus ex vivo expanded, TGF-β-imprinted universal-donor NK cells. The investigational NK cells are intended to provide immune-mediated tumor killing alongside chemotherapy.

ClinicalTrials.gov ID: NCT05634369

A First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted Il12 (Attil12)- T-Cell Therapy in Subjects With Advanced/Metastatic Soft Tissue and Bone Sarcoma

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Patients aged 12 years or older with locally advanced or metastatic soft-tissue or bone sarcoma, generally after prior systemic therapy, receive cyclophosphamide followed by engineered attIL12-T cells that display tumor-targeted interleukin-12 and bind cell-surface vimentin. The expansion cohort is limited to recurrent or metastatic unresectable osteosarcoma.

ClinicalTrials.gov ID: NCT05621668

A First-In-Human Phase I, Open Label, Safety and Tolerability Study of Escalating Multiple Doses of Intratumoral MQ710, a Multi-Transgene Expressing Modified Vaccinia Virus Ankara-Based Virotherapy, Alone and in Combination With the Systemic Checkpoint Inhibitor Pembrolizumab in Solid Tumors

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced or metastatic solid tumors after standard treatment, or with no suitable standard option, receive intratumoral MQ710 alone or with pembrolizumab; combination cohorts focus on cutaneous squamous cell carcinoma, Merkel cell carcinoma, melanoma, and head and neck squamous cell carcinoma, generally after anti–PD-1 therapy. MQ710 is an engineered vaccinia-based virotherapy designed to enhance cGAS–STING signaling and antitumor T-cell activity; pembrolizumab blocks PD-1.

ClinicalTrials.gov ID: NCT05859074

Novel RNA-lipid Particle (RNA-LP) Vaccine for Anti-PD-1 Antibody Therapy Sensitization

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with checkpoint-resistant melanoma or unresectable soft-tissue sarcoma receive a personalized vaccine made from their tumor mRNA in lipid particles, followed by resumed immune checkpoint inhibition. The vaccine is intended to deliver tumor antigens to antigen-presenting cells and stimulate tumor-specific T-cell responses.

ClinicalTrials.gov ID: NCT05264974